npj Vaccines (Oct 2022)

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern

  • Bassel Akache,
  • Tyler M. Renner,
  • Matthew Stuible,
  • Nazanin Rohani,
  • Yuneivy Cepero-Donates,
  • Lise Deschatelets,
  • Renu Dudani,
  • Blair A. Harrison,
  • Christian Gervais,
  • Jennifer J. Hill,
  • Usha D. Hemraz,
  • Edmond Lam,
  • Sophie Régnier,
  • Anne E. G. Lenferink,
  • Yves Durocher,
  • Michael J. McCluskie

DOI
https://doi.org/10.1038/s41541-022-00540-7
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed antigens based on the Beta & Delta variants of concern (VOC). These antigens elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain, while a multivalent vaccine generated cross-neutralizing activity in all three variants. This suggests that while current vaccines may be effective at reducing severe disease to existing VOC, variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses and reduce infection against arising variants.